2018 Global Antibody Drug Conjugates Market Forecasts to 2023: Rising Global Cancer Epidemics is Driving the Market

The Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023.

The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.

Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Market Dynamics

Drivers

Challenges

Key Topics Covered:

1. Research View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. Global Antibody Drug Conjugates Market Outlook to 2023

5. Commercialized Antibody Drug Conjugates

6. Antibody Drug Conjugates Pipeline Analysis

7. Drivers and Challenges

8. Major Potential Antibody Drug Conjugates in Pipeline

9. Trends and Developments

10. Strategic Alliances in the Global Antibody Drug Conjugates Industry

11. Competitive Assessment

For more information about this report visit https://www.researchandmarkets.com/research/9xj9xw/2018_global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716